BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27803004)

  • 1. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
    Boeck S; Mehraein Y; Ormanns S; Kruger S; Westphalen CB; Haas M; Jung A; Kirchner T; Heinemann V
    Ann Oncol; 2017 Feb; 28(2):438-439. PubMed ID: 27803004
    [No Abstract]   [Full Text] [Related]  

  • 2. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
    Luchini C; Grant RC; Scarpa A; Gallinger S
    Gut; 2021 Oct; 70(10):1809-1811. PubMed ID: 33468535
    [No Abstract]   [Full Text] [Related]  

  • 4. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
    Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
    Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
    Connor AA; Denroche RE; Jang GH; Timms L; Kalimuthu SN; Selander I; McPherson T; Wilson GW; Chan-Seng-Yue MA; Borozan I; Ferretti V; Grant RC; Lungu IM; Costello E; Greenhalf W; Palmer D; Ghaneh P; Neoptolemos JP; Buchler M; Petersen G; Thayer S; Hollingsworth MA; Sherker A; Durocher D; Dhani N; Hedley D; Serra S; Pollett A; Roehrl MHA; Bavi P; Bartlett JMS; Cleary S; Wilson JM; Alexandrov LB; Moore M; Wouters BG; McPherson JD; Notta F; Stein LD; Gallinger S
    JAMA Oncol; 2017 Jun; 3(6):774-783. PubMed ID: 27768182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
    Pishvaian MJ; Wang H; He AR; Hwang JJ; Smaglo BG; Kim SS; Weinberg BA; Weiner LM; Marshall JL; Brody JR
    Clin Cancer Res; 2020 Oct; 26(19):5092-5101. PubMed ID: 32669374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer.
    Bernstein Molho R; Zalmanoviz S; Laitman Y; Friedman E
    Fam Cancer; 2020 Apr; 19(2):193-196. PubMed ID: 31858328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
    Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.
    Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T
    J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.
    Couch FJ; Johnson MR; Rabe K; Boardman L; McWilliams R; de Andrade M; Petersen G
    Cancer Res; 2005 Jan; 65(2):383-6. PubMed ID: 15695377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping.
    Sharma MB; Carus A; Sunde L; Hamilton-Dutoit S; Ladekarl M
    Acta Oncol; 2016; 55(3):377-81. PubMed ID: 26004055
    [No Abstract]   [Full Text] [Related]  

  • 12. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer.
    Tsang ES; Walker EJ; Carnevale J; Fisher GA; Ko AH
    Immunotherapy; 2021 Oct; 13(15):1249-1254. PubMed ID: 34338034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer.
    Goldstein JB; Zhao L; Wang X; Ghelman Y; Overman MJ; Javle MM; Shroff RT; Varadhachary GR; Wolff RA; McAllister F; Futreal A; Fogelman DR
    Clin Cancer Res; 2020 Mar; 26(6):1385-1394. PubMed ID: 31871297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermutation In Pancreatic Cancer.
    Humphris JL; Patch AM; Nones K; Bailey PJ; Johns AL; McKay S; Chang DK; Miller DK; Pajic M; Kassahn KS; Quinn MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Stone A; Wilson PJ; Anderson M; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Waddell N; Wood S; Mead RS; Xu Q; Wu J; Pinese M; Cowley MJ; Jones MD; Nagrial AM; Chin VT; Chantrill LA; Mawson A; Chou A; Scarlett CJ; Pinho AV; Rooman I; Giry-Laterriere M; Samra JS; Kench JG; Merrett ND; Toon CW; Epari K; Nguyen NQ; Barbour A; Zeps N; Jamieson NB; McKay CJ; Carter CR; Dickson EJ; Graham JS; Duthie F; Oien K; Hair J; Morton JP; Sansom OJ; Grützmann R; Hruban RH; Maitra A; Iacobuzio-Donahue CA; Schulick RD; Wolfgang CL; Morgan RA; Lawlor RT; Rusev B; Corbo V; Salvia R; Cataldo I; Tortora G; Tempero MA; ; Hofmann O; Eshleman JR; Pilarsky C; Scarpa A; Musgrove EA; Gill AJ; Pearson JV; Grimmond SM; Waddell N; Biankin AV
    Gastroenterology; 2017 Jan; 152(1):68-74.e2. PubMed ID: 27856273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
    Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
    Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers.
    Yang C; Ceyhan-Birsoy O; Mandelker D; Jairam S; Catchings A; O'Reilly EM; Walsh MF; Zhang L
    Breast Cancer Res Treat; 2019 Jan; 173(1):79-86. PubMed ID: 30255452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma.
    Cloyd JM; Katz MHG; Wang H; Cuddy A; You YN
    JAMA Surg; 2017 Nov; 152(11):1086-1088. PubMed ID: 28793134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.